# 2024 SEMI-ANNUAL REPORT

SHANDONG WEIFANG RAINBOW CHEMICAL CO., LTD



Stock abbreviation:

Rainbow Chemical

Stock code:

301035







# NO.1 CHINA AGROCHEMICAL EXPORTERS

Ranked 1st in 2023 Ranked 1st in 2022 Ranked 1st in 2021 Ranked 1st in 2020

# NO.11 IN GLOBAL'S AGROCHEMICAL COMPANIES

Ranked 1 1th in 2022 Ranked 1 1th in 2021 Ranked 1 1th in 2020 Ranked 1 1th in 2019



# OPERATION ANALYSIS FOR THE FIRST HALF OF 2024

Impressive growth on B2C business	<ul> <li>The share of B2C revenue continues to rise: Increasing from 31.11% in 2023 to 37.52% in the reporting period.</li> <li>The gross margin of the B2C segment improves: Rising from 28.61% in 2023 to 29.21% in the reporting period.</li> <li>The B2B segment faces intense competition: This segment records a gross margin of 14.83%, with a year-on-year decrease of 2.45%. The higher revenue share of the B2B segment adversely affects the overall gross margin, which declines by 0.58%.</li> </ul>
Continued growth on insecticide and fungicide	<ul> <li>Revenue share continues to rise: Increasing from 18.05% in 2023 to 24.15% in the reporting period.</li> <li>Gross margin is higher than that of herbicides: Approximately 6% higher than the Company's traditional high-revenue herbicide category.</li> </ul>
Successful launch of biological Products	<ul> <li>Establishes a strategic plan for biological products, assembles a dedicated global team.</li> <li>The Company has successfully launched the first batch of products, which have received positive feedback. We expect to achieve a revenue target of USD 10 million for 2024.</li> </ul>
Significantly increased investment on IT and process	Accelerating efforts to enhance and improve the Company's global operational capabilities. This ensures that the Company can effectively manage and optimize its operations in the context of globalization.
Continuously increased investments on B2C development and global registrations	<ul> <li>Continued rapid enhancement of B2C business.</li> <li>Accelerating the investment of diverse and high-quality product registrations globally, with over 7,000 global registrations secured.</li> </ul>
Business in different regions	<ul> <li>Rapid growth in EU, North America, and Africa: The Company's Spanish subsidiary SARABIA, acquired at the end of 2022, and the US subsidiary APEX, acquired in early 2024, have both integrated successfully and are experiencing rapid growth. We anticipate continued strong growth in the EU and North America in the coming years. Our business in Africa, which began expanding in 2021, has also entered a rapid growth phase and is expected to continue growing strongly.</li> <li>Our business in Latin America, Asia-Pacific, and the Middle East is mature and continues to grow: Most countries have seen stable increases in gross and net margins alongside the rising share of our B2C business. However, our business in certain countries, especially Brazil, has been affected by a large amount of loss of unrealized exchange gains and losses arising from significant currency devaluation, sales seasonality, and high-cost inventory, which have negatively impacted our overall performance in the first half of this year in these countries.</li> </ul>



# OPERATIONAL OUTLOOK FOR THE SECOND HALF OF 2024

Continued recovery at the end markets
Significant improvement of operational quality

 We expect market demand to continue recovering in the second half of 2024, with end-market prices gradually returning to normal. As our B2C business revenue share continues to grow and our global operational capabilities improve, we anticipate that the gross margins of most subsidiaries in target countries will increase, and operational quality will be improved significantly. The foundation for the Company's healthy and stable growth remains solid, with a strong growth momentum.

#### Key tone:

- Focus on "quality improvement and efficiency enhancement": We aim to advance steadily, ensuring health, operational safety, and risk control while strengthening and expanding our business and achieving our vision.
- Enhance the Company's global operational capabilities, ensuring that the Company can
  effectively manage and optimize its operations in the context of globalization.

Build five critical capabilities that will become our core competitive strengths:

- · Global operational capability.
- Brand and channel development capability.
- Efficient, accurate and agile supply chain decision-making capability.
- Capability of successful commercialization of key products.
- High cost-performance and effective differentiated formulations technology capability.

### New five-year strategy plan (2025-2029)

#### Update our value proposition

- Portfolio Strength.
- Convenient Value.
- Efficient services.
- Reliable partnership.

#### Determine major growth strategies:

- · Increase the ratio of B2C business.
- Expand the scale of business in EU and North America.
- Increase the ratio of revenue from insecticide and fungicide.
- Strengthen business development in the biological products.



# MILESTONES IN H1 OF 2024



The Company is listed among Shandong Province's recognized local multinational companies

The Rainbow Leadership Program is officially launched





Argentine subsidiary receives the Belt and Road Cooperation Advancement Award

Completes the acquisition of a US preparations plant





Ranks the second in the 2024 Top 100 Chinese Pesticide Sales list

Signs a strategic cooperation agreement with Hebang





#### Complete industrial chain

- Keen insight into market trends to avoid the investment in R&D and manufacturing blindly.
- Harvest from the whole industrial chain including Technical synthesis, formulation, branding, Sales Channel(From Factory to Field).
- Based on a deep understanding of the whole process with "Light Structure, Fast response", calmly deal with major market fluctuation risks.

#### Unique business model

- Building an open "Quick Market Access Platform" globally.
- Combining the traditional export model with the overseas self-registration model.

# A clear strategic plan that is firmly implemented

- All staff focus on strategic planning and annual work plans to ensure the achievement of goals.
- Persisting in doing the difficult but correct work; Moving towards the forefront of industrial value chain;
   Building a complete industrial chain.



# Widely covered global marketing network

- Strong global registration capabilities and experienced international market development team.
- Having carried out businesses in more than 100 countries worldwide and continuing to accelerate the improvement of the global marketing network.

# Advanced manufacturing supported by R&D


- Advanced Manufacturing on more important Active ingredients.
- Differentiated formulation development focus to solve important pain points from end user market.

# Professional and dedicated international core team

- Publicity and implementation of vision, mission and core values to ensure cultural identity and consistency.
- Continuing to optimize positions, remuneration, performance, and training systems to build a talent echelon.



# A CLEAR AND FIRMLY IMPLEMENTED STRATEGY PLAN





# **Section I. Company Information and Key Financial Indicators**

## I. Company Profile

Stock abbreviation	润丰股份	Stock code	301035		
Listed on	Shenzhen Stock Exchange				
Chinese name of the Company	SHANDONG WEIFANG RAINBOW CHEMICAL CO.,LTD				
Chinese abbreviation of the Company (if any)	润丰股份				
Name of the Company in English (if any)	SHANDONG WEIFANG RAINBOW CHEMICAL CO.,LTD				
Abbreviation of the Company in English (if any)	RAINBOW CHEMICAL				
Legal representative of the Company	Wicky Wang				

### II. Person/Way to Contact

	Secretary of the board	Securities affairs representative
Name	Xing Bingpeng	Hu Dongju
Contact address	30th Floor, Building 5, Zone 5, Hanyu Financial Center, High-tech Zone, Jinan City, Shandong Province	30th Floor, Building 5, Zone 5, Hanyu Financial Center, High-tech Zone, Jinan City, Shandong Province
Tel	0531-83199916	0531-83199916
Fax	0531-83191676	0531-83191676
E-mail	rfzqb@rainbowagro.com	rfzqb@rainbowagro.com

### **III. Key Accounting Data and Financial Indicators**

Whether the Company needs to retroactively adjust or restate the accounting data of previous years

☐ Yes ☑ No

	H1 2024	H1 2023	Year-on-year increase or decrease
Operating income (RMB)	5,681,756,659.38	5,043,502,704.02	12.65%
Net profit attributable to shareholders of the Company (RMB)	181,794,252.02	424,390,802.78	-57.16%
Net profit attributable to shareholders of the Company excluding non-recurring gains and losses (RMB)	176,034,252.23	419,498,286.91	-58.04%
Net cash flow from operating	-138,751,214.78	-410,336,682.21	66.19%



activities (RMB)			
Basic earnings per share (RMB/Share)	0.65	1.53	-57.52%
Diluted earnings per share (RMB/Share)	0.65	1.52	-57.24%
Weighted average return on net assets	2.76%	6.77%	-4.01%
	End of this reporting period	End of the previous year	Increase or decrease at the end of this reporting period compared with the end of the previous year
Total assets (RMB)	15,436,142,454.55	14,897,954,098.13	3.61%
Net assets attributable to shareholders of the Company (RMB)	6,444,734,939.77	6,546,153,851.24	-1.55%

# IV. Items and Amounts of Non-recurring Gains and Losses

 $\ oxdot$  Applicable  $\ \Box$  Not applicable

Item	Amount	Notes
Gain and loss on disposal of non-current assets (including the write-off portion of asset impairment provision)	693,251.52	
Government subsidies included in current gains and losses (excluding those closely related to the Company's normal operational business, in compliance with national policies, received according to a determined standard, and having a continuous impact on the Company's profits and losses)	3,323,943.70	
Gains and losses arising from changes in the fair value of financial assets and financial liabilities held, and the gains and losses from the disposal of these financial assets and liabilities, excluding those related to effective hedging business connected with the Company's normal operations	442,401.49	
Other non-operating revenue and expenditure other than those mentioned above	727,061.99	
Other gains and losses items that meet the definition of non-recurring gains and losses	967,783.00	
Less: affected amount of income tax	383,346.83	
Affected amount of minority shareholders' equity (after tax)	11,095.08	



Total 5,759,999.79

Other gains and losses items that meet the definition of non-recurring gains and losses:

 $\ oxdot$  Applicable  $\ \Box$  Not applicable

The refund of individual income tax handling fees is the only item of other gains and losses that meets the definition of non-recurring gains and losses in the current reporting period.

# Section II. Discussion and Analysis of Management of the Company

#### I. The Main Business of the Company During the Reporting Period

#### (I). The situation of the industry during the reporting period

#### 1. Global crop protection market environment in H1 of 2024

- (1) The overall demand for crop protection products in the global market has become normal and is on the strong side. The prices of primary agricultural products remain at a historically reasonable median level. Farmers are willing to use pesticides, and the planting area of agricultural products has not decreased, indicating that the rigid consumption demand of end consumers for crop protection products is still there. According to the data from China's Customs for January to June 2024, the export volume under HS code 3808 increased by 52.70% year-on-year during this period. This indicates that the global market still has normal even strong demand for crop protection products.
- (2) During the reporting period, the prices of most active ingredients of crop protection products have stabilized at low levels. On June 30, 2024, the Sino-Agri price index for pesticide active ingredients was 76.14, representing a year-on-year decrease of 12.6%. However, while it is lower than the 80.19 recorded on December 31, 2023, the decline is relatively modest.

#### 2. Global Crop Protection Market Outlook for 2024

- (1) The prices of most crop protection active ingredients will continue to consolidate at the bottom. Most active ingredient prices have fallen to the new historical lowest level or even below that level, reaching a point where they can hardly decline further.

  However, due to the expansion and release of pesticide production capacity in China and India over the past three years, most active ingredients will continue to be in a situation of oversupply, which means that the prices of most active ingredients will continue to consolidate at the bottom.
- (2) Product pricing at its historical bottom can fluctuate significantly in the short term as a result of episodic events, which makes it more important to conduct inventory management and market strategy based on accurate decision-making and rapid response.



- (3) Dealers and end-users are significantly delaying their purchases. Due to the continuous decline in crop protection product prices over the past year and ample market supply, dealers and end-users are postponing their purchasing decisions compared to normal years. They prefer to wait until the last minute of the application season rather than planning or purchasing in advance, which poses a significant challenge to the supply chain organization of crop protection product sellers.
- (4) Market demand will continue to recover, and end-market prices will gradually return to rational levels. As high-cost inventories are cleared and previous irrational low-price clear-out sales by various companies significantly decrease, most end-markets are seeing a gradual increase in gross margins due to lower supply-side costs. Gross margins in the second half of the year are expected to improve compared to the first half.
- (5) The competitive landscape among leading global companies is adjusting more rapidly. This is marked by the continuous expansion of the market share of non-patented crop protection products and the resulting growth acceleration of excellent multinational companies in the non-patented protection product sector.

#### (II) Company operations during the reporting period

#### 1. Operation analysis for the first half of 2024

- (1) Impressive growth in B2C business: During the reporting period, the Company focuses intensively on growing its B2C segment, with B2C revenue share rising from 31.11% in the first half of 2023 to 37.52% in the reporting period. The B2C segment achieves a gross margin of 29.21%, with a year-on-year increase of 0.60%. In contrast, the B2B segment faces intense competition, with a gross margin of 14.83% and a year-on-year decrease of 2.45%. The higher revenue share of the B2B segment adversely affects the overall gross margin, which declines by 0.58%.
- (2) Continued growth in insecticide and fungicide revenue: Revenue from insecticides and fungicides continues to grow, with its share increasing from 18.05% in the first half of 2023 to 24.15% in the reporting period. The gross margin for insecticides and fungicides is approximately 6% higher than the Company's traditional high-revenue herbicide category.
- (3) Successful launch of new product category biological products: The Company establishes a strategic plan for biological products, assembles a dedicated global team, and has successfully launched the first batch of products, which have received positive feedback. We are confident in achieving a revenue target of USD 10 million for 2024.
- (4) The Company has significantly increased its investment in IT and process improvements, accelerating enhancements to its global operational capabilities.
- (5) The Company continues to increase investment in the B2C business and global registrations, driving the rapid growth of the B2C segment and accelerating the approvals of diverse and high-quality product registrations globally, particularly in high-barrier markets. We have now secured over 7,000 global registrations.



(6) Rapid growth in EU, North America, and Africa: The Company's Spanish subsidiary SARABIA, acquired in early 2023, and the US subsidiary APEX, acquired in early 2024, have both integrated successfully and are experiencing rapid growth. We anticipate continued strong growth in the EU and North America in the coming years. Our business in Africa, which began expanding in 2021, has also entered a rapid growth phase and is expected to continue growing strongly.

(7) Our business in Latin America, Asia-Pacific, and the Middle East is mature and continues to grow. Most countries have seen stable increases in gross and net margins alongside the rising share of our B2C business. However, our business in certain countries, especially Brazil, has been affected by a large amount of loss of unrealized exchange gains and losses arising from significant currency devaluation, sales seasonality, and high-cost inventory, which have negatively impacted our overall performance in the first half of this year in these countries.

#### 2. Operational outlook for the second half of 2024

We expect market demand to continue recovering in the second half of 2024, with end-market prices gradually returning to normal. As our B2C business revenue share continues to grow and our global operational capabilities improve, we anticipate that the gross margins of most subsidiaries in target countries will increase, and operational quality will be improved significantly. The foundation for the Company's healthy and stable growth remains solid, with a strong growth momentum.

We have completed the strategic planning for the next five years (2025-2029) in July and August. This timely planning will ensure that the Company remains focused on "quality improvement and efficiency enhancement" during industry downturns and intensifying competition. We aim to advance steadily, ensuring health, operational safety, and risk control while strengthening and expanding our business.

All employees will focus on the key tasks of the new strategic plan, aiming to look upward and move forward. We will make breakthroughs by building five critical capabilities that will become our core competitive strengths: global operational capability, brand and channel development capability, efficient, accurate and agile supply chain decision-making capability, capabilities of successful commercialization of key products, and high cost-performance and effective differentiated preparations technology capability.

#### II. Analysis on Main Businesses

Overview

See related content in "I. The Main Business of the Company During the Reporting Period".

Year-on-Year Changes of Key Financial Data



Unit: RMB

	H1 2024	H1 2023	Year-on-year increase or decrease	Reason for change
Operating income	5,681,756,659.38	5,043,502,704.02	12.65%	
Operating cost	4,532,572,886.98	3,994,055,439.67	13.48%	
Sales expenses	267,719,127.15	150,264,768.24	78.16%	Mainly caused by the increase in overseas employee remuneration, registration fees, travel expenses, consulting fees, and promotional expenses during the reporting period
Management expenses	212,412,218.74	228,737,334.76	-7.14%	
Financial expenses	310,963,592.68	-145,565,636.90	313.62%	Mainly caused by significant increase in exchange losses during the reporting period
Income tax expenses	70,960,584.49	66,302,826.32	7.02%	
R&D investment	150,650,332.37	126,654,808.20	18.95%	
Net cash flow from operating activities	-138,751,214.78	-410,336,682.21	66.19%	Mainly caused by the year-on-year increase in collected payments
Net cash flow in investment activities	-354,739,714.20	-425,349,554.24	16.60%	
Net cash flow from financing activities	715,610,089.11	423,248,244.58	69.08%	Mainly due to the increase in cash received from bank loans
Net increase in cash and cash equivalents	330,323,883.48	-415,720,363.05	179.46%	

Significant changes occurred in the composition or source of profits during the reporting period

□ Applicable ☑ N	Not applicable
------------------	----------------

No significant change occurred in the composition or source of profits during the reporting period.

Circumstances where products or services accounting for more than  $10\%\,$ 

 $\ oxdot$  Applicable  $\ \Box$  Not applicable

	Operating income	Operating cost	Gross profit margin	Year-on-year change of operating income	Year-on-year change of operating cost	Year-on-year change of gross profit margin
By product or ser	vice					
Major product- Herbicide	4,246,255,524.03	3,465,843,830.88	18.38%	4.69%	6.98%	-1.75%
Major product- Insecticide	791,815,967.12	577,099,940.26	27.12%	66.55%	57.83%	4.03%
Major product- Fungicide	580,255,873.17	451,114,119.00	22.26%	33.48%	30.53%	1.75%



## III. Analysis on Non-Major Businesses

 $oxed{\square}$  Applicable  $oxed{\square}$  Not applicable

Unit: RMB

	Amount	Proportion of total profits	Causes	
Investment returns	26,115,170.54	9.09%	Mainly due to investment gains from 9.09% the disposal of derivative financial assets	
Profits and losses of changes in fair values	19,010,682.28	6.62%	Mainly due to changes in the fair value of derivative financial assets	No
Asset Impairment	-739,835.93	-0.26%	Mainly due to the provision for inventory depreciation	No
Non-operating income	come 8,474,865.96 2.95% from scrapping to		Mainly due to incomes from scrapping non-current assets	No
Non-operating expenses	6,538,305.03	Mainly duc compensa		No
Credit impairment	-22,343,322.79	-7.77%	Mainly caused by credit impairment loss of accounts receivable	No
Other income	3,850,926.70	1.34%	Mainly due to government subsidies received	No

## IV. Analysis on Assets and Debts

### 1. Significant changes in asset composition

	End of this repo	rting period	End of the pre	vious year	Increase/	Notes on
	Amount	Proportion in total assets	Amount	Proportion in total assets	Decrease in proportion	significant changes
Monetary funds	3,121,731,820.65	20.22%	3,271,577,916.51	21.96%	-1.74%	
Accounts receivable	4,585,654,847.59	29.71%	4,707,041,417.82	31.60%	-1.89%	
Inventory	3,879,749,709.30	25.13%	3,336,332,619.58	22.39%	2.74%	
Investment real estate	8,200,121.02	0.05%	8,512,192.20	0.06%	-0.01%	
Long-term equity investment	1,224,240.06	0.01%	1,445,021.57	0.01%	0.00%	



Fixed assets	2,178,242,379.43	14.11%	2,008,437,417.28	13.48%	0.63%	
Construction in progress	344,527,308.70	2.23%	395,645,781.60	2.66%	-0.43%	
Assets with rights of use	16,886,806.52	0.11%	14,463,991.44	0.10%	0.01%	
Short-term loan	3,140,646,770.51	20.35%	2,261,455,023.95	15.18%	5.17%	Mainly due to the increase in short-term loans in the current period
Contract liability	57,775,336.59	0.37%	29,592,998.73	0.20%	0.17%	
Long-term loan	192,188,307.70	1.25%	77,624,331.91	0.52%	0.73%	
Lease liability	9,205,123.18	0.06%	8,219,602.23	0.06%	0.00%	

#### 2. Main overseas assets

 $\square$  Applicable ot in Mot applicable

#### 3. Assets and liabilities measured in fair value

 $\ oxdot$  Applicable  $\ \Box$  Not applicable

Unit: RMB ten thousand

ltem	Opening balance	Changes of gain or loss in fair values during the reporting period	Changes in accumulative fair values that are counted into equity	Impairment accrued during the reporting period	Purchase amount during the reporting period	Sales amount during the reporting period	Other changes	Ending Balance
Financial assets								
1. Trading financial assets (derivative financial assets excluded)	600.00				275.26	600.00		275.26
2. Derivative financial assets		1,590.22			3,974.88	2,489.45		1,485.43
Sub-total of financial assets	600.00	1,590.22			4,250.14	3,089.45		1,760.69
Receivables financing	50.00					50.00		0.00
The above total	650.00	1,590.22			4,250.14	3,139.45		1,760.69
Financial debts	414.16	310.85						92.22

Other changes

Whether there is any significant change to the Company's main asset measurements during the reporting period

☐ Yes ☑ No



# V. The Company's Profit Distribution and Conversion of Capital Reserve Fund into Share Capital During the Reporting Period

 $\ oxdot$  Applicable  $\ \Box$  Not applicable

Bonus shares per 10 shares (shares)	0
Dividends per 10 shares (RMB) (tax-inclusive)	1.80
Share capital base of the distribution plan (shares)	278,662,094
Cash dividend amount (RMB) (tax-inclusive)	50,159,176.92
Amount of cash dividends in other ways (such as share repurchase) (RMB)	0.00
Total cash dividends (including other ways) (RMB)	50,159,176.92
Distributable profit (RMB)	1,781,950,331.05
Proportion of total cash dividends (including other ways) in total distributable profit	100.00%

#### Details of the cash dividends distribution

If the development phase of the Company is in the growth phase and there exist material capital expenditure arrangements, when making profit distribution, the proportion of cash dividends in this profit distribution shall be at least 20%

Details of the plan for profit distribution or capital reserve converted into share capital

Based on the total share capital of 278,662,094 shares on July 30, 2024, a cash dividend of RMB 1.80 (tax inclusive) will be distributed to all shareholders for every 10 shares, and the remaining undistributed profits will be carried forward to the second half of this year. Except for the above-mentioned cash dividend distribution, no share dividend is distributed this time, and there is no conversion of capital reserve into share capital.

# **Section III. Financial Report**

#### I. Audit Report

M/hathar tl	he Half-Yea	r Donort ic	auditad
vviieillei il	HE DAH-18A	LPEDOLLS	audirea

☐ Yes ☑ No

The Company's Half-Year Report has not been audited.

#### **II. Financial Statements**

The currency of the statements in the financial notes is: RMB

#### 1. Consolidated balance sheet

Prepared by: Shandong Weifang Rainbow Chemical Co., Ltd.

Sunday, June 30, 2024

Item	Closing balance	Opening balance
Current assets:		
Monetary funds	3,121,731,820.65	3,271,577,916.51
Deposit reservation for balance		



institutions		
Financial assets held for trading	2,752,592.53	6,000,000.00
Derivative financial assets	14,854,334.92	
Notes receivable	15,874,927.66	55,955,879.66
Accounts receivable	4,585,654,847.59	4,707,041,417.82
Receivables financing		500,000.00
Pre-payments	175,108,524.23	129,020,462.65
Premium receivable		
Re-insurance accounts receivable		
Reserves for re-insurance contract receivable		
Other receivables	90,704,763.23	44,646,181.87
Including.: interest receivable		
Dividends receivable		
Financial assets purchased under resale agreement		
Inventory	3,879,749,709.30	3,336,332,619.58
Where: Data resource		
Contracted assets		
Assets held for sale		
Non-current assets that mature within		
one year		
Other current assets	286,410,808.65	329,901,506.56
Total current assets	12,172,842,328.76	11,880,975,984.65
Non-current assets:		
Disbursed loans and advances		
Debt investments		
Other debt investment		
Long-term receivables		
Long-term equity investment	1,224,240.06	1,445,021.57
Other equity instrument investment		
Other non-current financial assets		
Investment real estate	8,200,121.02	8,512,192.20
Fixed assets	2,178,242,379.43	2,008,437,417.28
Construction in progress	344,527,308.70	395,645,781.60
Productive biological assets		
Oil and gas assets		
Assets with rights of use	16,886,806.52	14,463,991.44
Intangible assets	205,334,544.65	214,122,877.97
Where: Data resource		
Development expenditure	115,599,813.72	36,791,601.49



Goodwill	94,866,025.56	94,866,025.56
Long-term deferred expenses	22,223,240.38	34,125,613.10
Deferred income tax assets	125,985,300.04	117,262,810.63
Other non-current assets	150,210,345.71	91,304,780.64
Total non-current assets	3,263,300,125.79	3,016,978,113.48
Total assets	15,436,142,454.55	14,897,954,098.13
Current liabilities:		
Short-term loan	3,140,646,770.51	2,261,455,023.95
Borrowings from the central bank		
Borrowing from banks and financial institutions		
Financial liabilities held for trading		
Derivative financial liabilities	922,206.24	4,141,579.45
Notes payable	3,186,508,732.46	4,057,148,069.12
Accounts payable	1,553,001,526.45	1,096,628,295.09
Advance receipts	212,056.37	232,358.87
Contract liability	57,775,336.59	29,592,998.73
Financial assets sold for repurchase		
Deposits and interbank deposits received		
Amount received from agency trading of securities		
Amount received from agency underwriting of securities		
Payroll payable	152,187,735.62	218,457,162.23
Taxes payable	63,424,887.74	77,730,510.55
Other payables	167,519,684.40	81,107,290.26
Including: Interests payable		
Dividends payable		
Charges and commissions payable		
Re-insurance accounts payable		
Liabilities held for sale		
Non-current liabilities due within one year	67,791,640.40	9,623,075.76
Other current liabilities	1,247,007.73	57,442,707.33
Total current liabilities	8,391,237,584.51	7,893,559,071.34
Non-current liabilities:		
Provision for insurance contracts		
Long-term loan	192,188,307.70	77,624,331.91
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liability	9,205,123.18	8,219,602.23



Long-term payables		
Long-term payroll payable		
Accrued liabilities		
Deferred income	10,777,796.13	11,713,887.21
Deferred income tax liabilities	59,828,236.73	67,145,243.72
Other non-current liabilities		
Total non-current liabilities	271,999,463.74	164,703,065.07
Total liabilities	8,663,237,048.25	8,058,262,136.41
Owner's equity:		
Share capital	278,662,094.00	278,662,094.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital reserve	2,393,443,152.29	2,382,932,252.27
Less: Treasury stock		
Other comprehensive income	-76,676,697.01	-53,797,771.67
Special reserve	46,413,216.36	38,596,260.53
Surplus reserve	158,674,657.07	158,674,657.07
General risk reserve		
Undistributed profit	3,644,218,517.06	3,741,086,359.04
Total owners' equity attributed to parent company	6,444,734,939.77	6,546,153,851.24
Minority shareholder's interest	328,170,466.53	293,538,110.48
Total owner's equity	6,772,905,406.30	6,839,691,961.72
Total liabilities and owners' equity	15,436,142,454.55	14,897,954,098.13

Legal Representative: Chief Accountant in Charge: Chief of Accounting Institution:
Wicky Wang Xing Bingpeng Zhang Baolin

## 2. Parent company balance sheet

Item	Closing balance	Opening balance
Current assets:		
Monetary funds	1,613,777,089.29	2,068,062,646.26
Financial assets held for trading	0.00	0.00
Derivative financial assets	0.00	0.00
Notes receivable	287,192.00	8,126,473.00
Accounts receivable	5,553,962,493.32	4,702,695,819.76
Receivables financing	0.00	500,000.00
Pre-payments	204,793,180.03	128,913,766.54
Other receivables	382,277,459.97	827,880,813.07
Including.: interest receivable	0.00	0.00
Dividends receivable	0.00	0.00
Inventory	719,071,212.50	734,862,014.63
Where: Data resource		
Contracted assets	0.00	0.00



Assets held for sale	0.00	0.00
Non-current assets that mature within one year	0.00	0.00
Other current assets	47,176,231.11	103,249,615.62
Total current assets	8,521,344,858.22	8,574,291,148.88
Non-current assets:		
Debt investments	0.00	0.00
Other debt investment	0.00	0.00
Long-term receivables	0.00	0.00
Long-term equity investment	624,321,060.99	624,541,993.45
Other equity instrument investment	0.00	0.00
Other non-current financial assets	0.00	0.00
Investment real estate	0.00	0.00
Fixed assets	1,041,859,022.15	970,475,370.21
Construction in progress	172,055,821.77	212,411,472.76
Productive biological assets	0.00	0.00
Oil and gas assets	0.00	0.00
Assets with rights of use	12,688,714.52	10,618,846.96
Intangible assets	38,186,270.00	39,286,592.63
Where: Data resource		
Development expenditure	107,509,528.91	36,742,669.45
Where: Data resource		
Goodwill	0.00	0.00
Long-term deferred expenses	3,311,926.61	3,428,134.55
Deferred income tax assets	24,036,804.78	23,421,436.66
Other non-current assets	53,757,938.07	42,380,243.97
Total non-current assets	2,077,727,087.80	1,963,306,760.64
Total assets	10,599,071,946.02	10,537,597,909.52
Current liabilities:		
Short-term loan	1,940,281,056.93	1,530,311,475.46
Financial liabilities held for trading	0.00	0.00
Derivative financial liabilities	0.00	0.00
Notes payable	2,310,892,647.60	3,173,804,324.86
Accounts payable	992,983,195.05	621,509,251.91
Advance receipts	0.00	0.00
Contract liability	11,159,157.91	8,721,263.54
Payroll payable	90,268,262.53	144,232,179.83
Taxes payable	8,246,618.13	3,769,917.28
Other payables	405,189,765.63	180,960,439.96
Including: Interests payable	0.00	0.00
Dividends payable	0.00	0.00
Liabilities held for sale	0.00	0.00



Non-current liabilities due within one year	4,560,445.18	8,261,043.80
Other current liabilities	1,247,007.73	9,385,795.08
Total current liabilities	5,764,828,156.69	5,680,955,691.72
Non-current liabilities:		
Long-term loan	150,000,000.00	0.00
Bonds payable	0.00	0.00
Including: Preferred shares	0.00	0.00
Perpetual bonds	0.00	0.00
Lease liability	4,871,430.46	4,862,142.34
Long-term payables	0.00	0.00
Long-term payroll payable	0.00	0.00
Accrued liabilities	0.00	0.00
Deferred income	1,272,004.54	1,474,705.66
Deferred income tax liabilities	43,494,641.66	43,494,641.66
Other non-current liabilities	0.00	0.00
Total non-current liabilities	199,638,076.66	49,831,489.66
Total liabilities	5,964,466,233.35	5,730,787,181.38
Owner's equity:		, , ,
Share capital	278,662,094.00	278,662,094.00
Other equity instruments	0.00	0.00
Including: Preferred shares	0.00	0.00
Perpetual bonds	0.00	0.00
Capital reserve	2,400,240,106.19	2,389,729,206.17
Less: Treasury stock	0.00	0.00
Other comprehensive income	0.00	0.00
Special reserve	15,078,524.36	13,004,013.98
Surplus reserve	158,674,657.07	158,674,657.07
Undistributed profit	1,781,950,331.05	1,966,740,756.92
Total owner's equity	4,634,605,712.67	4,806,810,728.14
Total liabilities and owners' equity	10,599,071,946.02	10,537,597,909.52

#### 3. Consolidated income statement

Item	First half year of 2024	First half year of 2023
I. Gross Operating Income	5,681,756,659.38	5,043,502,704.02
Including: Operating income	5,681,756,659.38	5,043,502,704.02
Interest income		
Premium earned		
Handling charges and commissions income		
II. Total Operating Costs	5,422,424,326.73	4,366,319,713.41
Including: Costs of business	4,532,572,886.98	3,994,055,439.67
Interest expenses		
Handling charges and commission	_	



expenses		
Surrender value		
Net payments for insurance claims		
Net withdrawal of reserve for insurance		
responsibility contracts		
Expenditures of policy dividend		
Re-insurance expense		
Taxes and surcharges	26,914,381.04	12,172,999.44
Sales expenses	267,719,127.15	150,264,768.24
Management expenses	212,412,218.74	228,737,334.76
R&D expenditures	71,842,120.14	126,654,808.20
Financial expenses	310,963,592.68	-145,565,636.90
Including: Interest expenses	58,196,033.29	18,521,750.06
Interest income	22,157,882.37	25,979,037.84
Add: Other incomes	3,850,926.70	5,541,198.21
Income from investment ("-" for loss)	26,115,170.54	-138,011,157.94
Including: Income from investment in		135,511,13113
associated enterprises and joint ventures	-220,781.51	-224,332.54
Income recognized at termination of financial assets measured at amortized cost		
Foreign exchange gain ("-" for loss)		
Net exposure hedging income ("-" for loss)		
Income from changes in fair value ("-" for loss)	19,010,682.28	-29,696,287.71
Credit impairment losses ("-" for loss)	-22,343,322.79	7,648,337.17
Asset impairment losses ("-" for loss)	-739,835.93	-3,911,947.90
Gains from asset disposal ("-" for loss)	224,678.18	-442,817.59
III. Operating profit ("-" for loss)	285,450,631.63	518,310,314.85
Add: Non-operating income	8,474,865.96	6,288,109.44
Less: Non-operating expenses	6,538,305.03	6,560,502.52
IV. Total profit ("-" for total loss)	287,387,192.56	518,037,921.77
Less: Income tax expenses	70,960,584.49	66,302,826.32
V. Net profit ("-" for net loss)	216,426,608.07	451,735,095.45
(I) Classification by business continuity	220) 120)333137	102,700,000110
1. Net profit from continuing operations	216,426,608.07	451,735,095.45
("-" for net loss)	210,420,000.07	+51,755,055.45
2. Net profit from discontinued operations ("-" for net loss)		
(II) Classification by ownership		
1. Net profit attributable to shareholders	181,794,252.02	424,390,802.78
of the parent company ("-" for net loss)	101,734,232.02	+24,330,602.76
2. Profit and loss of minority shareholders ("-" for net loss)	34,632,356.05	27,344,292.67
VI. Net amount after tax of other	-22,878,925.34	15,286,792.86



comprehensive income		
Net amount of other comprehensive		
income after tax attributed to the	-22,878,925.34	6,814,695.35
owners of parent company	22,070,323.34	0,014,033.33
(I) Other comprehensive income that		
cannot be reclassified into profit or loss		
1. Changes due to re-measurement on		
defined benefit plan		
2. Other comprehensive income that		
cannot be converted into profit and loss		
under the equity method		
3. Changes in fair value of other equity		
instrument investments		
4. Changes in the fair value of the credit		
risk of the enterprise		
5. Other		
(ii) Other comprehensive income that		
will be reclassified into profit and loss	-22,878,925.34	6,814,695.35
1. Other comprehensive income that can		
be converted to profit or loss under the		
equity method		
2. Changes in fair value for other		
investment on bonds		
3. Amount of financial assets reclassified		
into other comprehensive income		
4. Provision for credit impairment of		
other creditor's rights investment		
5. Cash flow hedge reserve		
6. Difference of foreign currency	-22,878,925.34	6,814,695.35
financial statement translation	-22,676,323.34	0,614,093.33
7. Other		
Net amount of other comprehensive		
income after tax attributed to minority	0.00	8,472,097.51
shareholders		
VII. Total comprehensive income	193,547,682.73	467,021,888.31
Total comprehensive income attributed	158,915,326.68	431,205,498.13
to parent company owners	130,313,320.08	431,203,430.13
Total comprehensive income attributed	34,632,356.05	35,816,390.18
to minority shareholders	34,032,330.03	33,010,330.16
VIII. Earnings per Share:		
(i) Basic earnings per share	0.65	1.53
(ii) Diluted earnings per share	0.65	1.52

For business combination under the same control in the current period, the net profit of the merged party before the business combination is RMB , and the net profit of the merged party in the previous period is RMB .

Legal Representative:		Chief Accountant in Charge:	Chief of Accounting Institution:
	Wicky Wang	Xing Bingpeng	Zhang Baolin



## 4. Income statement of the parent company

		Unit: RMB
Item	First half year of 2024	First half year of 2023
I. Operating income	3,776,707,791.28	3,752,460,171.54
Less: operating cost	3,507,244,191.11	3,176,969,600.08
Taxes and surcharges	6,281,374.35	4,240,898.12
Sales expenses	67,879,398.57	73,912,445.93
Management expenses	67,066,449.58	101,070,285.87
R&D expenditures	63,929,706.30	106,993,024.19
Financial expenses	-33,901,338.44	-76,293,760.31
Including: Interest expenses	29,851,977.51	5,146,390.60
Interest income	13,531,089.54	19,349,574.45
Add: Other incomes	2,356,305.96	1,683,129.45
Income from investment ("-" for loss)	18,562,000.78	-130,089,232.64
Including: Income from investment in associated enterprises and joint ventures	-220,781.51	-224,332.54
Income recognized at termination of financial assets measured at amortized cost		
Net exposure hedging income ("-" for loss)		
Income from changes in fair value ("-" for loss)		2,721,440.50
Credit impairment losses ("-" for loss)	-8,432,236.26	-1,199,960.04
Asset impairment losses ("-" for loss)	93,739.98	721,452.06
Gains from asset disposal ("-" for loss)	5,559.91	
II. Operating profit ("-" for loss)	110,793,380.18	239,404,506.99
Add: Non-operating income	2,412,960.61	2,352,570.26
Less: Non-operating expenses	3,563,425.21	3,167,383.13
III. Total profit ("-" for total loss)	109,642,915.58	238,589,694.12
Less: Income tax expenses	15,771,247.48	27,555,811.19
IV. Net profit ("-" for net loss)	93,871,668.10	211,033,882.93
(I) Net profit from continuing operations	93,871,668.10	211,033,882.93
("-" for net loss)  (II) Net profit from discontinued	, ,	, , , , , , , , , , , , , , , , , , , ,
operations ("-" for net loss)		
V. Other comprehensive income, net of		
taxes		
(I) Other comprehensive income that		
cannot be reclassified into profit or loss  1. Changes due to re-measurement on		
defined benefit plan		
2. Other comprehensive income that cannot be converted into profit and loss		



under the equity method		
3. Changes in fair value of other equity		
instrument investments		
4. Changes in the fair value of the credit		
risk of the enterprise		
5. Other		
(ii) Other comprehensive income that		
will be reclassified into profit and loss		
1. Other comprehensive income that can		
be converted to profit or loss under the		
equity method		
2. Changes in fair value for other		
investment on bonds		
3. Amount of financial assets reclassified		
into other comprehensive income		
4. Provision for credit impairment of		
other creditor's rights investment		
5. Cash flow hedge reserve		
6. Difference of foreign currency		
financial statement translation		
7. Other		
VI. Total comprehensive income	93,871,668.10	211,033,882.93
VII. Earnings per share:		
(i) Basic earnings per share		
(ii) Diluted earnings per share		

#### 5. Consolidated cash flow statement

Item	First half year of 2024	First half year of 2023
I. Cash Flows Generated from Operating Activities:		
Cash received from sales of goods and services	6,098,881,356.71	5,209,507,192.15
Net increase in deposit from customers and interbank		
Net increase in borrowing from central bank		
Net increase in borrowings from other financial institutions		
Cash receipts from premiums under direct insurance contracts		
Net cash receipts from re-insurance business		
Net cash receipts from policyholders' deposits and investments		
Cash receipts from interest, handling fees and commissions		
Net increase in capital borrowed from banks and other financial institutions		
Net increase in repurchase business capital		
Net cash received from securities		



trading brokerage		
Cash receipts from tax refunds	390,028,063.11	366,285,872.74
Cash received relating to other operating activities	115,824,970.74	37,137,117.11
Subtotal of cash inflow in business activities	6,604,734,390.56	5,612,930,182.00
Cash payments for goods acquired and services received	5,799,850,517.80	5,149,241,199.50
Net increase in customer loans and advances		
Net increase in deposits in central bank and interbank		
Cash payments for original insurance contract claims		
Net increase in lending funds from banks and other financial institutions		
Cash payments for interest, fee and commission		
Cash payments for insurance policyholder dividends		
Cash payments to employees and on behalf of employees	474,840,586.27	355,664,363.13
Cash payments for taxes	153,815,653.42	153,361,010.96
Other cash payments relating to operating activities	314,978,847.85	365,000,290.62
Subtotal of cash outflow in business activities	6,743,485,605.34	6,023,266,864.21
Net cash flow from operating activities	-138,751,214.78	-410,336,682.21
II. Cash Flows from Investing Activities:		
Cash receipts from investment		
withdrawal		
Cash receipts from return on		
investments		
Net cash receipts from disposals of fixed assets, intangible assets and other long-term assets	25,129,385.57	1,512,492.93
Net cash receipts from disposal of subsidiary or any other business unit		
Other cash receipts relating to investing activities	28,976,011.37	
Subtotal of cash inflow in investment activities	54,105,396.94	1,512,492.93
Cash payments to acquire or construct fixed assets, intangible assets and other long-term assets	408,845,111.14	292,265,778.15
Cash payments for investment		
Net increase in pledged loans		
Net cash payments to acquire subsidiary and other business units		
Other cash payments relating to investment activities		134,596,269.02
Subtotal of cash outflow in investment	408,845,111.14	426,862,047.17



Net cash flow in investment activities	-354,739,714.20	-425,349,554.24
III. Cash Flows from Financing Activities:		
Cash received from capital contributions		
Including: Cash received from		
investment of minority shareholder from		
subsidiary		
Cash receipts from borrowings	2,818,924,833.84	643,103,333.82
Other cash receipts relating to financing activities		367,622,937.23
Subtotal of cash inflow in financing		
activities	2,818,924,833.84	1,010,726,271.05
Cash repayments of borrowings	1,766,456,617.44	155,414,609.48
Cash payments for distribution of		
dividends, profits, or cash payments for	336,858,127.29	432,063,416.99
interest expenses		
Including: Dividends and profits paid to		
minority shareholders by subsidiaries		
Other cash paid related to financing		
activities		
Subtotal of cash outflow in financing	2,103,314,744.73	587,478,026.47
activities	2,103,314,744.73	307,470,020.47
Net cash flow from financing activities	715,610,089.11	423,248,244.58
IV. Effect of Exchange Rate Changes on	108,204,723.35	-3,282,371.18
Cash and Cash Equivalents	100,204,723.33	3,202,371.10
V. Net Increase in Cash and Cash	330,323,883.48	-415,720,363.05
Equivalents	333,323,663.46	.13,720,303.03
Add: Beginning balance of cash and cash	1,185,554,395.09	2,076,062,785.79
equivalents		
VI. Closing Balance of Cash and Cash	1,515,878,278.57	1,660,342,422.74
Equivalents		

## 6. Cash flow statement of the parent company

Item	First half year of 2024	First half year of 2023
I. Cash Flows Generated from Operating		
Activities:		
Cash received from sales of goods and services	3,017,021,578.12	3,764,322,572.59
Cash receipts from tax refunds	315,650,646.17	282,124,895.16
Cash received relating to other operating activities	386,675,610.32	57,423,972.12
Subtotal of cash inflow in business activities	3,719,347,834.61	4,103,871,439.87
Cash payments for goods acquired and services received	2,657,901,466.52	3,769,545,098.51
Cash payments to employees and on behalf of employees	201,124,025.91	228,681,544.43
Cash payments for taxes	46,568,226.23	53,248,479.32
Other cash payments relating to operating activities	994,641,806.92	468,420,296.63
Subtotal of cash outflow in business activities	3,900,235,525.58	4,519,895,418.89
Net cash flow from operating activities	-180,887,690.97	-416,023,979.02



II. Cash Flows from Investing Activities:		
Cash receipts from investment		
withdrawal		
Cash receipts from return on		
investments		
Net cash receipts from disposals of fixed		
assets, intangible assets and other long-	308,286.60	2,468,815.63
term assets	300,200.00	2,100,013.03
Net cash receipts from disposal of		
subsidiary or any other business unit		
Other cash receipts relating to investing		
activities	18,603,136.95	
Subtotal of cash inflow in investment		
activities	18,911,423.55	2,468,815.63
Cash payments to acquire or construct		
fixed assets, intangible assets and other	146,426,522.21	211,451,033.47
long-term assets		
Cash payments for investment		
Net cash payments to acquire subsidiary		
and other business units		
Other cash payments relating to	F12 022 0C	120 004 000 10
investment activities	512,833.96	129,864,900.10
Subtotal of cash outflow in investment	146,939,356.17	341,315,933.57
activities	140,939,330.17	341,313,933.37
Net cash flow in investment activities	-128,027,932.62	-338,847,117.94
III. Cash Flows from Financing Activities:		
Cash received from capital contributions		
Cash receipts from borrowings	2,023,710,035.75	461,930,020.30
Other cash receipts relating to financing	1,202,628.69	353,486,465.55
activities	1,202,028.03	333,460,403.33
Subtotal of cash inflow in financing	2,024,912,664.44	815,416,485.85
activities	2,024,312,004.44	013,410,403.03
Cash repayments of borrowings	1,468,138,593.88	155,066,307.66
Cash payments for distribution of		
dividends, profits, or cash payments for	307,654,408.71	424,716,774.32
interest expenses		
Other cash paid related to financing		
activities		
Subtotal of cash outflow in financing	1,775,793,002.59	579,783,081.98
activities		
Net cash flow from financing activities	249,119,661.85	235,633,403.87
IV. Effect of Exchange Rate Changes on	39,648,688.36	13,876,340.98
Cash and Cash Equivalents	22,2 :2,388:88	
V. Net Increase in Cash and Cash	-20,147,273.38	-505,361,352.11
Equivalents	, ,	, , -
Add: Beginning balance of cash and cash equivalents	472,609,515.86	1,201,820,433.48
VI. Closing Balance of Cash and Cash		
Equivalents	452,462,242.48	696,459,081.37



# 7. Consolidated statement of changes in owners' equity

Amount in the current period

							First h	alf year o	f 2024						
					Equity	attributed to	o owners of the par								
Item	Share capital	Other ed	quity instrum Perpetual bonds	Other	Capital	Less: Treasury stock	Other comprehensive income	Special reserve	Surplus	General risk reserve	Undistributed profit	Other	Subtotal	Minority shareholder's interest	Total owner's equity
I. Balance at the end of the previous year:	278,662,094.00				2,382,9 32,252. 27		-53,797,771.67	38,596, 260.53	158,674,6 57.07		3,741,086,35 9.04		6,546,153,85 1.24	293,538,110.4	6,839,691,961.7 2
Add: Changes in accounting policies															
Correction of errors from previous period															
Other  II. Opening balance of the current year	278,662,094.00				2,382,9 32,252. 27		-53,797,771.67	38,596, 260.53	158,674,6 57.07		3,741,086,35 9.04		6,546,153,85 1.24	293,538,110.4	6,839,691,961.7
III. Changes in Current Period ("-" for decrease)					10,510, 900.02		-22,878,925.34	7,816,9 55.83			96,867,841.9 8		- 101,418,911. 47	34,632,356.05	-66,786,555.42
(I) Total comprehensiv e income							-22,878,925.34				181,794,252. 02		158,915,326. 68	34,632,356.05	193,547,682.73
(II) Capital contribution and reduction by owners					10,510, 900.02								10,510,900.0		10,510,900.02
1. Ordinary shares invested by owners													0.00		
2. Capital contributed from other equity instrument holders													0.00		
3. Amounts of share-based payments recognized in owners'					10,510, 900.02								10,510,900.0		10,510,900.02



					ı				1	
equity										
4. Other								0.00		
(III) Profit							-	-		
distribution							278,662,094.	278,662,094.		-278,662,094.00
							00	00		
1.										
Appropriation								0.00		
of surplus										
reserve										
2.										
Appropriation								0.00		
of general risk										
reserve										
3. Distribution							-	-		
to owners (or							278,662,094.	278,662,094.		-278,662,094.00
shareholders)							00	00		
4. Other										
(IV) Internal										
carry-over of								0.00		
owners'								0.00		
equity										
1. Capital										
reserve										
converted								0.00		
into capital								0.00		
(or share										
capital)										
2. Surplus										
reserve										
converted								0.00		
into capital										
(or share										
capital)										
3. Recovery of										
losses by								0.00		
surplus										
reserves										
4. Carry-over										
retained										
earnings from								0.00		
defined										
benefit plan changes										
5. Carry-over										
retained earnings from										
other								0.00		
comprehensiv										
e income										
								0.00		
6. Other								0.00		
(V) Special					7,816,9			7,816,955.83		7,816,955.83
reserves					55.83					



Withdrawal     in the current     period					20,775, 360.08			20,775,360.0		20,775,360.08
2. Use in the current period					12,958, 404.25			- 12,958,404.2 5		-12,958,404.25
IV. Balance at the end of the current period	278,662,094.00		2,393,4 43,152. 29	-76,676,697.01		158,674,6 57.07	3,644,218,51 7.06	6,444,734,93 9.77	328,170,466.5	6,772,905,406.3

Amount of previous year

														<u> </u>	iic. Kivib
							First h	alf year o	f 2023					T.	
					Equity	attributed t	o owners of the pa	rent comp	any						
Item	Share capital	Other e  Preferred  shares	quity instrun Perpetual bonds	Other	Capital	Less: Treasury stock	Other comprehensive income	Special reserve	Surplus	General risk reserve	Undistributed profit	Other	Subtotal	Minority shareholder's interest	Total owner's equity
I. Balance at the end of the previous year:	277,115,744.00				2,301,2 93,600. 92		5,821,782.13	19,551, 007.62	158,674,6 57.07		3,421,808,37 4.82		6,184,265,16 6.56	202,957,841.2	6,387,223,007.8
Add: Changes in accounting policies															
Correction of errors from previous period															
Other															
II. Opening balance of the current year	277,115,744.00				2,301,2 93,600. 92		5,821,782.13	19,551, 007.62	158,674,6 57.07		3,421,808,37 4.82		6,184,265,16 6.56	202,957,841.2	6,387,223,007.8
III. Changes in Current Period ("-" for decrease)					23,877, 383.06		6,814,695.35	11,174, 404.11			27,307,859.9 4		14,558,622.5	32,604,742.14	47,163,364.72
(I) Total comprehensiv e income							6,814,695.35				424,390,802. 78		431,205,498. 13	35,816,390.18	467,021,888.31
(II) Capital contribution and reduction by owners					23,877, 383.06								23,877,383.0		23,877,383.06
1. Ordinary shares invested by owners															
2. Capital contributed															



	1								1		
from other											
equity											
instrument											
holders											
2.4											
3. Amounts of											
share-based											
payments			23,877,						23,877,383.0		23,877,383.06
recognized in			383.06						6		
owners'											
equity											
4. Other											
(III) Profit							454 600 662		454 600 662	2 244 640 04	45404004076
distribution							451,698,662.		451,698,662.		-454,910,310.76
							72		72		
1.											
Appropriation											
of surplus											
reserve											
2.											
Appropriation											
of general risk											
reserve											
3. Distribution							-		-		
to owners (or							451,698,662.		451,698,662.	-3,211,648.04	-454,910,310.76
shareholders)							72		72		
4. Other											
(IV) Internal											
carry-over of											
owners'											
equity											
1. Capital											
reserve											
converted											
into capital											
(or share											
capital)											
2. Surplus											
reserve											
converted											
into capital											
(or share											
capital)					<u></u>					<u></u>	
3. Recovery of											
losses by											
surplus											
reserves											
4. Carry-over											
retained											
earnings from											
defined											
benefit plan											
changes											
	<u> </u>			1	l			1	1	I .	



5. Carry-over retained earnings from other comprehensiv e income										
(V) Special reserves					11,174, 404.11			11,174,404.1		11,174,404.11
Withdrawal in the current period					20,466, 859.24			20,466,859.2	177,574.85	20,644,434.09
2. Use in the current period					9,292,4 55.13			9,292,455.13	-177,574.85	-9,470,029.98
(VI) Other										
IV. Balance at the end of the current period	277,115,744.00		2,325,1 70,983. 98	12,636,477.48	30,725, 411.73	158,674,6 57.07	3,394,500,51 4.88	6,198,823,78 9.14	235,562,583.3	6,434,386,372.5 3

### 8. Statement of changes in owner's equity of the parent company

Amount in the current period

						Firs	t half year of 202	24				
Item	Share capital	Other ed Preferred shares	quity instrui Perpetual bonds	nents Other	Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserve	Surplus reserve	Undistributed profit	Other	Total owner's equity
I. Balance at the end of the previous year:	278,662,0 94.00				2,389,729 ,206.17			13,004,0 13.98	158,674,657. 07	1,966,740,756. 92		4,806,810,72 8.14
Add: Changes in accounting policies												
Correction of errors from previous period												
Other												
II. Opening balance of the current year	278,662,0 94.00				2,389,729 ,206.17			13,004,0 13.98	158,674,657. 07	1,966,740,756. 92		4,806,810,72 8.14
III. Changes in Current Period ("-"					10,510,90 0.02			2,074,51 0.38		- 184,790,425.8 7		- 172,205,015. 47



for decrease)							
(I) Total comprehensi ve income						93,871,668.13	93,871,668.1
(II) Capital contribution and reduction by owners			10,510,90 0.02				10,510,900.0 2
1. Ordinary shares invested by owners							
2. Capital contributed from other equity instrument holders 3. Amounts of share-							
based payments recognized in owners' equity			10,510,90 0.02				10,510,900.0 2
4. Other							
(III) Profit distribution						278,662,094.0 0	278,662,094. 00
1. Appropriatio n of surplus reserve							
2. Distribution to owners (or shareholders )						- 278,662,094.0 0	- 278,662,094. 00
3. Other (IV) Internal carry-over of owners' equity 1. Capital reserve							
converted into capital (or share capital)  2. Surplus							



reserve									
converted									
into capital									
(or share									
capital)									
3. Recovery									
of losses by									
surplus									
reserves									
4. Carry-over									
retained									
earnings									
from defined									
benefit plan									
changes									
5. Carry-over									
retained									
earnings									
from other									
comprehensi									
ve income									
6. Other									
(V) Special						2,074,51			
reserves						0.38			2,074,510.38
1.						0.50			
Withdrawal									
in the						10,963,7			10,963,770.1
current						70.14			4
period									
2. Use in the						-			_
current						8,889,25			8,889,259.76
period						9.76			
(VI) Other									
IV. Balance									
at the end of	278,662,0			2,400,240				1,781,950,331.	4,634,605,71
the current	94.00			,106.19		24.36	07	05	2.67
period									

Amount in the previous period

		First half year of 2023											
Item	Chaus	Other equ	uity instrum	ents	Causital.	Less: Treasury stock	Other	C	Constant	Undistributed		Total	
item	capital	Preferred shares	Perpetual bonds	Other	Capital reserve		comprehensive income	Special reserve	Surplus reserve	profit	Other	owner's equity	
I. Balance at													
the end of	277,115,7				2,307,349,				158,674,657.	2,189,570,288.		4,932,710,64	
the previous	44.00				954.34				07	45		3.86	
year:													
Add:													
Changes in													
accounting													



policies								
Correction of								
errors from								
previous								
period								
Other								
II. Opening	277 115 7		2 207 240			150 674 657	2 400 570 200	4,932,710,64
balance of the current	277,115,7 44.00		2,307,349, 954.34			158,674,657.	2,189,570,288. 45	3.86
year								
III. Changes								
in Current			24,839,10		7,812,10		- 240,664,779.7	208,013,571.
Period ("-"			0.00		8.54		240,004,779.7	208,013,371.
for decrease)								
(I) Total							211,033,882.9	211,033,882.
comprehensi ve income							3	93
(II) Capital								
contribution								
and			24,839,10					24,839,100.0
reduction by			0.00					0
owners								
1. Ordinary								
shares invested by								
owners								
2. Capital								
contributed								
from other								
equity instrument								
holders								
3. Amounts								
of share-								
based			24,839,10					24,839,100.0
payments			0.00					0
recognized in owners'								
equity								
4. Other								
							-	-
(III) Profit distribution							451,698,662.7	451,698,662.
							2	72
1.								
Appropriation of surplus								
reserve								
2.								
Distribution							-	-
to owners							451,698,662.7	451,698,662.
(or							2	72
shareholders								



)								
) 3. Other								
(IV) Internal carry-over of owners' equity								
1. Capital reserve converted into capital (or share capital)								
2. Surplus reserve converted into capital (or share capital)								
3. Recovery of losses by surplus reserves 4. Carry-over								
retained earnings from defined benefit plan changes								
5. Carry-over retained earnings from other comprehensi ve income								
6. Other								
(V) Special reserves					7,812,10 8.54			7,812,108.54
1. Withdrawal in the current period					13,682,7 70.35			13,682,770.3 5
2. Use in the current period (VI) Other					5,870,66 1.81			5,870,661.81
IV. Balance at the end of the current period	277,115,7 44.00		2,332,189, 054.34		7,812,10 8.54	158,674,657. 07	1,948,905,508. 66	4,724,697,07 2.61



In case of any discrepancies between English and Chinese versions of the "2024 Semi-Annual Report," the Chinese version shall prevail.

SHANDONG WEIFANG RAINBOW CHEMICAL CO.,LTD

**Board of Directors** 

Sep. 10, 2024